ABSTRACT Daidzein has become increasingly popular as a dietary supplement, particularly for postpeakestrus animals, as a safe and natural alternative estrogen-like compound. However, there is little available safety data of daidzein in laying hens. A study was conducted to examine if high-dose daidzein affected the safety of hens, including mortality, laying performance, egg quality, hematological parameters, clinical chemical parameters, organ development parameters, and hatchability. A total of 2,448 42-wk-old Rugao laying hens were randomly assigned to 4 groups with 6 replicates of 102 birds each (612 laying hens per group). After a 2-wk acclimation period, the birds were fed diets supplemented with 0, 10, 100, or 200 mg/kg of daidzein for 12 wk. The hatchability of setting eggs increased linearly with increasing dietary daidzein supplementation (P = 0.034), while the hatchability of fertile eggs also tended to increase linearly (P = 0.069). The red cell distribution width (RCDW) and coefficient variation of RCDW showed an increasing and then decreasing quadratic response to increasing dietary daidzein supplementation (P = 0.001 and 0.002, respectively). No statistically significant changes were observed in mortality, laying performance, egg quality, clinical chemistry parameters, or organ development parameters (P > 0.05). The magnitude of these hematological changes was such that they were considered to be of no toxicological significance. Therefore, a nominal daidzein concentration of 200 mg/kg is not expected to cause adverse effects following daily administration to laying hens for 84 d.
INTRODUCTION
Soybeans are rich in isoflavones, which are naturally synthesized from phenylpropanoids and simple phenols with a structure similar to that of estradiol. Daidzein and genistein are the predominant isoflavones of soybeans (Lissin and Cooke, 2000) . Soybeans contain approximately 540 mg of daidzein and 670 mg of genistein per kilogram (Franke et al., 1994) . The structure of daidzein resembles that of endogenous estrogen and has the capability of binding to estrogen receptors α and β (Martin et al., 1978) , but with a much lower affinity. Daidzein can compete with estradiol for binding to the estrogen β receptor and, once bound, can increase the expression of estrogen-responsive genes (Ni et al., 2007; Liu and Zhang, 2008) . Because of its ability to exert estrogenic activity, daidzein and related compounds are referred to as phytoestrogens.
Epidemiological reports have associated soy products with the prevention of certain types of cancer, a re-duced risk of osteoporosis, the ability to lower plasma cholesterol, and activity as antioxidant agents and immune enhancers in humans and other animals (Messina, 2010) . Several recent studies have investigated mechanisms of action and possible health benefits of daidzein (Liu and Zhang, 2008; Nynca et al., 2009; Messina, 2010; Atkinson et al., 2012) , although public health recommendations regarding daidzein intake remain controversial. Much of this uncertainty has focused on potential adverse effects of daidzein and its metabolites in estrogen-sensitive tissues. By binding to and transactivating estrogen receptors, daidzein can induce proliferation of estrogen-sensitive endometrial and breast tumor cells in culture (Markiewicz et al., 1993; Wang et al., 1996; Hsieh et al., 1998) and elicit clear estrogenic effects in rodent models, particularly when given as purified supplements (Hsieh et al., 1998; Ju et al., 2001; Allred et al., 2004) . Naturally, this evidence has raised concern that high levels of daidzein intake may promote negative effects in estrogen-responsive tissues in women and female animals.
While traditional soybean-based poultry diets provide 7 to 10 mg/d of daidzein (Saitoh et al., 2001) , commercially available purified supplements may deliver far greater amounts of daidzein (>30 mg per serving), 2098 despite little relevant safety data at these doses. Also, there have been few conventional sub-chronic and chronic safety studies published regarding daidzein supplementation in livestock. Hence, our group has conducted several studies to evaluate the safety of daidzein in Hy-Line laying hens Shi et al., 2013) . Therefore, as part of an extensive program to evaluate the safety of daidzein, we conducted an 84-d feeding study of local laying hens (Rugao laying hens) to determine whether high-dose daidzein affects the safety of hens, including mortality, laying performance, egg quality, hematology, clinical chemistry parameters, organ development parameters, and hatchability. Highdose daidzein was chosen to provide significant exposure to the test material, while other dose levels were set to provide adequate data for risk assessment.
MATERIALS AND METHODS

Study Design
A total of 2,448 42-wk-old Rugao laying hens were randomly assigned to 4 groups with 6 replicates of 102 birds each (612 laying hens per group). All birds were acclimated to a basal diet for 2 wk. At the end of wk 44 (the late stage of the egg production cycle), the birds were fed diets supplemented with 0 (control), 10 [the maximum recommended available dose (MRAD)], 100 (10-fold of MRAD), and 200 mg/kg (20-fold of MRAD) daidzein for 12 wk. The content of daidzein in each diet is 59.78, 76.44, 152.77, and 247.26 mg/kg, respectively (measured values) . Clinical observations, mortality, laying performance, and egg quality were measured, and at the end of wk 56, the animals were killed and subjected to a full post-mortem examination. The wing vein blood samples were collected for clinical pathological examinations, while selected organs were weighed and specified tissues were collected for subsequent histological examinations. Fertility and hatchability were measured from wk 57 to 58.
Birds, Diet, and Management
This trial was carried out at the Poultry Institute, Chinese Academy of Agricultural Sciences. Daidzein was derived from soybeans (Sichuan Guanghan Feed Co. Ltd., Sichuan, China) with 98.5% purity. Three birds were housed in individual 50 × 40-cm cages, providing 666 cm 2 per bird, under a 16:8-h light-dark cycle at a constant temperature of 20 ± 3
• C and 65 to 75% relative humidity. Table 1 presents the composition of the experimental diets. Water and feed were provided ad libitum during the study period. All animal handing protocols were approved by Animal Care and Use Committee of the Poultry Institute.
Sample Collection and Analytical Determination
Observations Cage-side observations, which included recording any changes in clinical condition or behavior, were made at least twice daily throughout the study period.
Laying Performance Daily egg production and egg weight were monitored during the trial. Laying rate is expressed as average hen-day production, calculated from the total number of eggs divided by the total number of days. Feed intake was recorded on a replicate basis at weekly intervals. Feed conversion was expressed as grams of feed consumed per grams of eggs produced.
Fertility and Hatchability From the end of wk 56, the remaining birds in the 4 groups were subjected to artificial insemination and hatching eggs were collected for 14 d for evaluation of fertility and hatchability. Hatching was carried out in accordance with the incubation program in the same incubator (Qingdao Xingyi Electronic Equipment Co. Ltd., Shandong, China). Fertility, hatchability of fertile eggs, and hatchability of setting eggs were determined.
Egg Quality Freshly laid eggs were collected at the end of wk 56. For each examination, the internal and external characteristics of 36 randomly selected eggs per group (6 eggs/ replicate) were measured. The time interval between the eggs being laid and measured was less than 24 h. The eggs were stored at room temperature before measurement. The length and width of the eggs were measured using the FHK egg shape determinator (Fujihira Industry Co., Tokyo, Japan) and the egg shape index was calculated (width/length × 100). Eggshell color was measured using the EQ Reflectometer (Fujihira Industry Co.) at 3 places (i.e., blunt region, equatorial region, and sharp region) with the average used for analyses. Eggshell strength was evaluated using the EggShell Force Gauge (Robotmation Co. Ltd., Tokyo, Japan). Egg weight, albumen height, Haugh unit (HU), and yolk color were measured using the Egg Multi Tester EMT-5200 (Robotmation Co. Ltd., Tokyo, Japan). Then, the yolk and albumen were separated and individually weighed. The eggshell was weighed with the eggshell membrane intact. Eggshell thickness without the inner membranes was measured at the blunt, equatorial, and sharp regions to obtain an average value. The ratios of yolk, albumen, and eggshell to egg weight were calculated. Clinical Blood Parameters At the end of the 84-d feeding period (56 wk), wing vein blood samples for hematological analysis and clinical chemistry were collected at necropsy from 96 birds (4 birds from each replicate, 24 birds per group); 1.5 mL of blood was collected in EDTA-containing tubes for hematological analysis, whereas 2.5 mL of blood was collected for chemical analysis. The following hematological parameters of the collected samples were measured using a Sysmex XE2100 automated hematology analyzer (Sysmex Corporation, Kobe, Japan): white blood cells, red blood cells, hemoglobin, hematocrit, mean hematocrit, mean hemoglobin, mean hemoglobin concentration, red cell distribution width (RCDW), and coefficient variation of RCDW.
Calcium, phosphorus, glucose, total cholesterol, and triglycerides were measured in serum collected from blood samples centrifuged at 3,500 × g for 10 min at 4
• C using a biochemical analyzer (UniCel DxC 800 Synchron; Beckman Coulter, Inc., Brea, CA). These parameters were included to cover a wide range of possible toxicities to include possible effects on electrolyte balance, metabolism (carbohydrates, fat, and minerals), and damage to the major organ systems.
Necropsy All blood samples were collected from birds (n = 96) killed by exsanguination and subjected to a full post-mortem examination. At necropsy, the heart, liver, spleen, lung, kidney, and pancreas were weighed (paired organs were weighed together).
Statistical Analysis
All data were analyzed using SPSS statistical software (SPSS 16.0 for Windows; IBM-SPSS Inc., Chicago, IL). One-way analysis of variance (ANOVA) followed by Duncan's multiple comparison test was used to evaluate different means among treatments. Data were assumed to be statistically significant at P < 0.05.
RESULTS
Mortality and Observations
Mortality of hens during the entire experimental period was unaffected by dietary daidzein supplementation (P = 0.318, Table 2 ). No treatment-related adverse clinical signs were observed.
Laying Performance
The mean laying rate, average egg weights, average daily egg mass, average daily feed intake, and feed conversion values are shown in Table 2 . No statistically significant differences were found among all laying performance parameters observed in either the treated group or the control group (P = 0.509, 0.139, 0.621, 0.291, and 0.584, respectively).
Fertility and Hatchability
No statistically significant change was noted in fertility (P = 0.239, Table 2 ). The hatchability of setting eggs increased linearly with increasing dietary daidzein supplementation (P = 0.034), while the hatchability of fertile eggs also tended to increase linearly (P = 0.069).
Egg Quality
External and internal egg qualities for layers administered different doses of daidzein are shown in Table 3 . There were no significant difference in any of the egg quality traits (P > 0.05). 
Clinical Blood Parameters
No statistically significant changes were observed in hematological parameters (P > 0.05, Table 4 ) except for RCDW and coefficient variation of RCDW. The RCDW and coefficient variation of RCDW showed an increasing and then decreasing quadratic response to increasing dietary daidzein supplementation (P = 0.001 and 0.002, respectively). However, in the absence of any significant organ changes or macroscopic histopathological findings in these birds, the magnitude of these hematology changes were such that they were considered to be of no toxicological significance. No clinical chemical parameters were significantly affected by dietary daidzein supplementation (P > 0.05, Table 5 ).
Necropsy
After 12 wk of daidzein treatment, no statistically significant changes were observed in organ development in comparison to the concurrent control animals (Table 6 ). For birds that survived to termination, no histopathological findings or macroscopic findings were noted at necropsy that could be attributed to daidzein administration.
DISCUSSION
Diets containing daidzein were well tolerated and produced no general, organ or systemic toxicity when fed to laying hens at doses as high as 200 mg/kg of the diet for a period of 84 d. No macroscopic observations were noted at necropsy and no histological changes were considered to be related to treatment. In addition, these doses did not adversely affect mortality, laying performance, egg quality, clinical chemistry parameters, organ development parameters, or cause any treatmentrelated clinical signs. Some changes were observed in hematological parameters, but these changes were minor and considered to be of no toxicological significance. The fertility and hatchability were considered to be biologically influenced by daidzein consumption.
There are few published conventional safety studies available for daidzein despite widespread interest in its use as a chemopreventive agent for a variety of diseases and cancer. There are numerous studies that were generally conducted for reasons other than a comprehensive evaluation of a variety of safety endpoints. Zhao et al. (2004 Zhao et al. ( , 2005 found that daidzein supplementation improved postpeak egg production of Shaoxing ducks in a dose-dependent manner. Shi et al. (2013) found that 50 mg of dietary daidzein per kilogram of feed significantly improved egg production during the postpeak period of Hyline Brown laying hens. Ni et al. (2007) and Liu and Zhang (2008) also found similar results in laying hens. Gu et al. (2013) found that longer-term use of high-dose daidzein (100 mg/kg) increased bone mineralization and effectively improved eggshell quality during the postpeak period of Hyline Brown laying hens. In the present study, no statistically significant differences were found in laying performance or fertility, and no toxicological significance on hematological parameters was found at necropsy, which was in conflict with the results of many previous studies (Zhao et al., 2004 (Zhao et al., , 2005 Ni et al., 2007; Liu and Zhang, 2008; Gu et al., 2013; Shi et al., 2013) . On the one hand, this could be because daidzein can serve as an agonist to occupy vacant estrogen-binding sites, resulting in an overall increase in the systemic estrogenic effect, thereby up-regulating mRNA expression of gonadotropin receptors to improve follicle development and laying performance after the peak laying period (Cassidy, 2003; Liu and Zhang, 2008) . Except for the agonistic effect, daidzein can also act as an antagonist by competing with estrogen for estrogen receptors, but produces a much weaker estrogenic response when endogenous estrogen levels are high (Setchell and Cassidy, 1999) . This was ascertained in the present study, in which the RCDW and coefficient variation of RCDW showed significant increasing and then decreasing quadratic responses to increasing dietary daidzein supplementation, and the hatchability of setting eggs and fertile eggs increased linearly with increasing dietary daidzein supplement. These changes were considered to have resulted from the hormonal effects of daidzein. On the other hand, the different results between this experiment and previous studies might be related to the differences in genetics. The breed used in the current experiment was a local laying hen, which was not the same as that used in those experiments (Zhao et al., 2004 (Zhao et al., , 2005 Ni et al., 2007; Liu and Zhang, 2008; Gu et al., 2013; Shi et al., 2013) . Therefore, further studies are needed to elucidate the molecular mechanism(s) underlying this phenomenon.
The major objective of the current study was to examine the clinical and safety parameters of daidzein in healthy laying hens. Consumption of daidzein for 84 d appeared to induce no adverse side effects or undesirable changes in clinical chemical, hematological, or urological parameters. The absence of side effects is in agreement with the observations in earlier clinical and safety studies Shi et al., 2013) .
In conclusion, our study findings revealed that longer-term use of high-dose daidzein could increase the hatchability of setting eggs and fertile eggs. In the absence of any significant changes in mortality, laying performance, egg quality, clinical chemistry parameters, or organ development parameters, the magnitude of these hematological changes was such that they were considered to be of no toxicological significance. Therefore, a nominal daidzein concentration of 200 mg/kg is not expected to cause adverse effects following daily administration to laying hens for 84 d.
